Best Agrolife Q1 FY27: Revenue ₹396 Cr, PAT ₹41 Cr; Margins Improve Significantly
Best Agrolife reported Q1 FY27 revenue of ₹396 crore, up 4% YoY. PAT surged 104% to ₹41 crore from ₹20 crore in Q1 FY26. Gross margin improved to 37% and EBITDA margin to 20%. The company launched new patented products and bio-stimulants, contributing to market acceptance.
The strong financial performance, particularly the doubling of PAT and significant margin improvement, coupled with the introduction of new patented products, is expected to have a high impact on investor sentiment and the company's market position.
The company reported significant year-on-year growth in revenue and a substantial increase in profit after tax, alongside improved margins. The launch of new products and positive commentary from the Managing Director also contribute to a positive sentiment.
Best Agrolife Limited has announced its financial results for the first quarter of FY27, ending June 30, 2026. The company reported a revenue of ₹396 crore, a 4% increase from ₹381 crore in Q1 FY26. The gross margin saw a substantial improvement to 37% from 29% in the previous year, driven by a 37% increase in the volume of patented products. EBITDA margin rose to 20% from 12% in Q1 FY26, attributed to higher gross margins and operating leverage. Profit After Tax (PAT) more than doubled to ₹41 crore from ₹20 crore in Q1 FY26, resulting in a PAT margin of 10% compared to 5% in the prior year. Sequentially, the company showed significant strengthening, with revenue, EBITDA, and PAT returning to profitability compared to Q4 FY26.
The Managing Director, Mr. Vimal Kumar, noted that despite a delayed monsoon and uneven rainfall affecting Kharif sowing and crop protection purchases, the company delivered revenue growth and improved profitability. Key products like Best ManTM, FetagenTM, Warden ExtraTM, and RonfenTM continued to gain market acceptance, with newly launched patented products FluzamTM and Cubax Power ExtraTM also witnessing increasing adoption. However, irregular rainfall patterns and delayed sowing impacted demand for seed treatment products and crop protection in certain regions. The company remains confident about the demand outlook with improving monsoon activity. The improvement in gross and EBITDA margins reflects a focus on product mix, operational efficiency, price increases, and cost management. Best Agrolife remains focused on innovation, market presence expansion, price increases, and operational efficiency to create sustainable value.
The company also highlighted its strong portfolio of patented products, including Warden ExtraTM, FetagenTM, NemagentM, RonfenTM, Shot DowntM, TricolorTM, Best ManTM, DinotrexTM, FluzamTM, Cubax Power ExtraTM, and MidcotintM. Additionally, it introduced new bio-stimulants and plant growth regulators such as SprinkTM, PunctualTM, TornetTM, EmproleTM, and Richgrow GoldTM. The company's manufacturing capabilities include 7000 MTPA Technical and 35500 KL Formulation capacity, with over 530 formulations and 800+ registrations. Best Agrolife is recognized as the 13th largest Indian Agrochemical Company and operates across 21 states with 11+ manufacturing units and over 10,900 dealers.
What to do with a filing like this
Best Agrolife Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Best Agrolife Limited. Read the original for the full detail.